Breaking News Instant updates and real-time market news.

2018-09-13 07:46:52 VZ Verizon $54.96 / +0.24 (+0.44%) , BABA Alibaba $161.49 / +4.11 (+2.61%) … 07:46 09/13/18 09/13 07:46 09/13/18 07:46	Verizon in focus as former AOL chief Armstrong confirms exit Tim Armstrong is leaving Oath, the Verizon (VZ) unit that encompasses both Yahoo and AOL, the company confirmed on Wednesday. He will be succeeded by Oath's chief operating officer K. Guru Gowrappan, who joined earlier this year from Alibaba (BABA). ARMSTRONG OUT: Tim Armstrong, the founder of Oath, is leaving the company at the end of the year, confirming reports last week that said Armstrong was in talks to depart. Armstrong came to Verizon in 2015 as part of the company's acquisition of AOL, where he had served as CEO. Verizon later acquired Yahoo and combined it with AOL into a new unit called Oath. Armstrong had attempted to build a digital advertising business to compete with Google (GOOG, GOOGL) and Facebook (FB), but the efforts so far have failed to generate much growth. According to a recent Wall Street Journal report, Verizon recently discussed whether to spin off the Oath business, but instead decided to integrate the unit more fully with the rest of the company's operations. Armstrong had pushed Verizon in recent months to better use its retail stores to promote Oath's services such as the ability to watch NFL football games on Yahoo Sports, sources said. GOWRAPPAN IN: K. Guru Gowrappan, who has been president and chief operating officer of Oath since April, will take over as CEO on October 1, with Armstrong remaining an adviser until the end of the year. "Guru has proven experience in scaling businesses globally. I'm thrilled he will lead Oath in an exciting new phase of growth, building on the foundation Tim and his team have created," Verizon CEO Hans Vestberg said in a statement." WHAT'S NOTABLE: This summer, Lowell McAdam stepped down as CEO of Verizon and was succeeded by Vestberg, the telecom company's chief technology officer and EVP and president of global networks. According to reports, by selecting Vestberg as CEO, Verizon's board signalled that it is continuing to focus on investments in wireless networks and technology, including building out a nationwide 5G broadband network, rather than media. PRICE ACTION: Verizon is fractionally lower in pre-market trading. VZ Verizon $54.96 / +0.24 (+0.44%) BABA Alibaba $161.49 / +4.11 (+2.61%) GOOG Alphabet $1,162.64 / -15.16 (-1.29%) GOOGL Alphabet Class A $1,171.51 / -18.13 (-1.52%) FB Ticker changed to META $162.00 / -3.96 (-2.39%)	13 Sep 18 Sep 20 Sep 27 Sep 28 Sep 21 Oct 28 Oct

2018-09-13 07:46:52

Verizon

$54.96 / +0.24 (+0.44%)

, BABA

Alibaba

$161.49 / +4.11 (+2.61%)

… 07:46

09/13/18

09/13

07:46

09/13/18

07:46

Verizon in focus as former AOL chief Armstrong confirms exit

Tim Armstrong is leaving Oath, the Verizon (VZ) unit that encompasses both Yahoo and AOL, the company confirmed on Wednesday. He will be succeeded by Oath's chief operating officer K. Guru Gowrappan, who joined earlier this year from Alibaba (BABA). ARMSTRONG OUT: Tim Armstrong, the founder of Oath, is leaving the company at the end of the year, confirming reports last week that said Armstrong was in talks to depart. Armstrong came to Verizon in 2015 as part of the company's acquisition of AOL, where he had served as CEO. Verizon later acquired Yahoo and combined it with AOL into a new unit called Oath. Armstrong had attempted to build a digital advertising business to compete with Google (GOOG, GOOGL) and Facebook (FB), but the efforts so far have failed to generate much growth. According to a recent Wall Street Journal report, Verizon recently discussed whether to spin off the Oath business, but instead decided to integrate the unit more fully with the rest of the company's operations. Armstrong had pushed Verizon in recent months to better use its retail stores to promote Oath's services such as the ability to watch NFL football games on Yahoo Sports, sources said. GOWRAPPAN IN: K. Guru Gowrappan, who has been president and chief operating officer of Oath since April, will take over as CEO on October 1, with Armstrong remaining an adviser until the end of the year. "Guru has proven experience in scaling businesses globally. I'm thrilled he will lead Oath in an exciting new phase of growth, building on the foundation Tim and his team have created," Verizon CEO Hans Vestberg said in a statement." WHAT'S NOTABLE: This summer, Lowell McAdam stepped down as CEO of Verizon and was succeeded by Vestberg, the telecom company's chief technology officer and EVP and president of global networks. According to reports, by selecting Vestberg as CEO, Verizon's board signalled that it is continuing to focus on investments in wireless networks and technology, including building out a nationwide 5G broadband network, rather than media. PRICE ACTION: Verizon is fractionally lower in pre-market trading.

Verizon

$54.96 / +0.24 (+0.44%)

BABA

Alibaba

$161.49 / +4.11 (+2.61%)

GOOG

Alphabet

$1,162.64 / -15.16 (-1.29%)

GOOGL

Alphabet Class A

$1,171.51 / -18.13 (-1.52%)

Ticker changed to META

$162.00 / -3.96 (-2.39%)

13
Sep
18
Sep
20
Sep
27
Sep
28
Sep
21
Oct
28
Oct

OTHER BREAKING NEWS FROM THE FLY

Recommendations	Pacific Biosciences price target raised to $7.50 from $6 at Piper Sandler » 21:42 08/17/22 08/17 21:42 08/17/22 21:42 PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on Pacific Biosciences to $7.50 from $6 and keeps a Neutral rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/17/22 Cathie Wood's ARK Investment bought 340K shares of Pacific Biosciences today 08/16/22 Cathie Wood's ARK Investment bought 173.7K shares of Pacific Biosciences today 08/11/22 Pacific Biosciences trading resumes 08/11/22 Pacific Biosciences trading halted, volatility trading pause PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 08/04/22 Canaccord Pacific Biosciences price target lowered to $14 from $17 at Canaccord 05/15/22 Piper Sandler Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler 05/05/22 Cantor Fitzgerald Pacific Biosciences price target lowered to $19 from $23 at Cantor Fitzgerald PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/03/22 Pacific Biosciences now sees 2022 revenue $138M-$145M, consensus $161.95M 08/03/22 Pacific Biosciences reports Q2 non-GAAP EPS (34c), consensus (32c) 05/04/22 Pacific Biosciences reports Q1 EPS (37c), consensus (31c) PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/04/22 What You Missed On Wall Street On Thursday 08/04/22 What You Missed On Wall Street This Morning 07/21/22 What You Missed On Wall Street This Morning 07/01/22 What You Missed On Wall Street On Friday 08/22/22 Pacific Biosciences - PACB 08/23/22 Pacific Biosciences PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/10/22 Pacific Biosciences call volume above normal and directionally bullish 08/03/22 Pacific Biosciences options imply 13.0% move in share price post-earnings 03/18/22 Pacific Biosciences call volume above normal and directionally bullish
Recommendations	OncoCyte price target raised to $1.50 from $1.40 at Piper Sandler » 21:42 08/17/22 08/17 21:42 08/17/22 21:42 OCX OncoCyte / + Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on OncoCyte to $1.50 from $1.40 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events OCX OncoCyte / + 07/13/22 OncoCyte announces market entry, early adopter program with VitaGraft 07/06/22 OncoCyte presents data on DetermaIO cancer test at ESMO congress 06/22/22 OncoCyte hosting KOL webinar on DetermaIO 05/26/22 OncoCyte presents DetermaIO data at ASCO supporting immunotherapy expansion OCX OncoCyte / + 08/11/22 Lake Street OncoCyte price target lowered to $3 from $6 at Lake Street 05/24/22 Stephens Stephens downgrades OncoCyte to Equal Weight on limited near-term upside 05/24/22 Stephens OncoCyte downgraded to Equal Weight from Overweight at Stephens 05/15/22 Piper Sandler OncoCyte price target lowered to $1.40 from $1.80 at Piper Sandler OCX OncoCyte / + 08/10/22 OncoCyte reports Q2 EPS (7c) vs (12c) last year 05/11/22 OncoCyte reports Q1 EPS (11c), consensus (12c) 03/10/22 OncoCyte reports Q4 EPS (39c), consensus (13c) 14 Apr OCX OncoCyte / + 04/18/22 Fly Insider: Sonic Automotive, Moderna among week's notable insider trades 04/13/22 Fly Intel: After-Hours Movers 09/14/22 6th Annual Best Ideas Growth Conference: Big 6
Recommendations	Invitae price target lowered to $2.25 from $2.50 at Piper Sandler » 21:42 08/17/22 08/17 21:42 08/17/22 21:42 NVTA Invitae $4.25 / -0.2 (-4.50%) Piper Sandler analyst… Piper Sandler analyst David Westenberg lowered the firm's price target on Invitae to $2.25 from $2.50 and keeps an Underweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options NVTA Invitae $4.25 / -0.2 (-4.50%) 08/17/22 Cathie Wood's ARK Investment bought 1.11M shares of Invitae today 08/15/22 Invitae rises 11.4% 08/12/22 Invitae rises 29.0% 08/12/22 Invitae rises 20.6% NVTA Invitae $4.25 / -0.2 (-4.50%) 08/10/22 JPMorgan Invitae cut to Underweight at JPMorgan with future growth yet to be proven 08/10/22 JPMorgan Invitae downgraded to Underweight from Neutral at JPMorgan 07/26/22 Cowen Invitae cut to Market Perform at Cowen on debt refinancing uncertainty 07/26/22 Cowen Invitae downgraded to Market Perform from Outperform at Cowen NVTA Invitae $4.25 / -0.2 (-4.50%) 08/09/22 Invitae backs FY22 revenue growth of low double digits, consensus $542.96M 08/09/22 Invitae reports Q2 adjusted EPS (68c), consensus (76c) 07/18/22 Invitae sees second half of FY22 revenue flat over first half of FY22 07/18/22 Invitae sees Q2 revenue $136M, consensus $142.74M NVTA Invitae $4.25 / -0.2 (-4.50%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 07/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 Fly Intel: After-Hours Movers 09/10/22 ESMO Congress 2022 NVTA Invitae $4.25 / -0.2 (-4.50%) 08/12/22 Unusually active option classes on open August 12th 08/11/22 Invitae call buyer realizes 3500% same-day gains 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings
Recommendations	Natera price target raised to $70 from $60 at Piper Sandler » 21:42 08/17/22 08/17 21:42 08/17/22 21:42 NTRA Natera $52.53 / -2.595 (-4.71%) Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on Natera to $70 from $60 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly NTRA Natera $52.53 / -2.595 (-4.71%) 08/11/22 Natera completes enrollment in RenaCARE study 08/10/22 Natera announces Q-Sub filing with FDA for its Panorama NIPT 07/18/22 Natera says Federal Circuit affirms September 2021 decision on CareDx patents 07/18/22 Medicare extends coverage of Natera's Signatera MRD test NTRA Natera $52.53 / -2.595 (-4.71%) 08/05/22 JPMorgan Natera price target raised to $100 from $80 at JPMorgan 07/18/22 Piper Sandler Natera CMS decision will drive more tests, says Piper Sandler 07/14/22 Piper Sandler Piper says Natera selection for UnitedHealth network validates practices 05/15/22 Piper Sandler Natera price target lowered to $60 from $75 at Piper Sandler NTRA Natera $52.53 / -2.595 (-4.71%) 08/04/22 Natera raises FY22 revenue view to $805M-$825M from $790M-$810M 08/04/22 Natera reports Q2 EPS ($1.50), consensus ($1.50) 05/05/22 Natera raises 2022 revenue view to $790M-$810M from $770M-$790M 05/05/22 Natera reports Q1 EPS ($1.45), consensus ($1.48) NTRA Natera $52.53 / -2.595 (-4.71%) 03/11/22 Hindenburg says Natera response 'ignored many of the major issues' NTRA Natera $52.53 / -2.595 (-4.71%) 08/05/22 Sell these stocks now, proven algorithm says 04/29/22 Proven algorithm says sell these stocks now 03/15/22 What You Missed On Wall Street On Tuesday 03/15/22 What You Missed On Wall Street This Morning
Recommendations	NeoGenomics price target raised to $19 from $13 at Piper Sandler » 21:41 08/17/22 08/17 21:41 08/17/22 21:41 NEO NeoGenomics $11.64 / -0.45 (-3.72%) Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on NeoGenomics to $19 from $13 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options NEO NeoGenomics $11.64 / -0.45 (-3.72%) 07/21/22 NeoGenomics appoints Chris Smith as CEO 07/21/22 NeoGenomics names Chris Smith CEO 06/03/22 NeoGenomics receives CAP certfication in Suzhou China laboratory 05/16/22 NeoGenomics appoints Lynn Terault as interim CEO NEO NeoGenomics $11.64 / -0.45 (-3.72%) 07/08/22 Piper Sandler CMS proposal changes little for test companies, says Piper Sandler 06/02/22 Piper Sandler NeoGenomics initiated with an Overweight at Piper Sandler 03/29/22 Cowen NeoGenomics price target lowered to $24 from $42 at Cowen 03/29/22 BTIG NeoGenomics price target lowered to $28 from $35 at BTIG NEO NeoGenomics $11.64 / -0.45 (-3.72%) 08/09/22 NeoGenomics reports Q2 EPS (28c), consensus (22c) 08/09/22 NeoGenomics reports Q2 revenue $125M, consensus $123.33M 04/27/22 NeoGenomics reports Q1 adjusted EPS (20c), consensus (23c) 04/26/22 Notable companies reporting before tomorrow's open NEO NeoGenomics $11.64 / -0.45 (-3.72%) 08/12/22 Sell these stocks now, proven algorithm says 07/29/22 Sell these stocks now, proven algorithm says 07/01/22 Sell these stocks now, proven algorithm says 05/06/22 Proven algorithm says sell these stocks now 09/10/22 ESMO Congress 2022 NEO NeoGenomics $11.64 / -0.45 (-3.72%) 05/04/22 Largest borrow rate increases among liquid names
Recommendations	Exact Sciences price target lowered to $40 from $50 at Piper Sandler » 21:41 08/17/22 08/17 21:41 08/17/22 21:41 EXAS Exact Sciences $39.56 / -1.54 (-3.75%) Piper Sandler analyst… Piper Sandler analyst David Westenberg lowered the firm's price target on Exact Sciences to $40 from $50 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings Events Options EXAS Exact Sciences $39.56 / -1.54 (-3.75%) 08/03/22 Cathie Wood's ARK Investment bought 20.4K shares of Exact Sciences today 08/02/22 MDxHealth acquires Oncotype DX from Exact Sciences for $100M in cash, stock 08/02/22 Exact Sciences enters collaboration with West German Study Group 07/12/22 Cathie Wood's ARK Investment bought 49.2K shares of Exact Sciences today EXAS Exact Sciences $39.56 / -1.54 (-3.75%) 08/03/22 Craig-Hallum Exact Sciences price target lowered to $60 from $81 at Craig-Hallum 08/03/22 Cowen Exact Sciences price target lowered to $67 from $83 at Cowen 08/03/22 BTIG Exact Sciences price target lowered to $70 from $100 at BTIG 08/03/22 Baird Exact Sciences price target lowered to $75 from $90 at Baird EXAS Exact Sciences $39.56 / -1.54 (-3.75%) 08/02/22 Exact Sciences lowers FY22 revenue view to $1.980B-$2.022B from $1.985B-$2.032B 08/02/22 Exact Sciences reports Q2 EPS (94c), consensus ($1.07) 08/02/22 Notable companies reporting after market close 04/26/22 Exact Sciences raises FY22 revenue view to $1.985-$2.032 from $1.975B-$2.027B 08/29/22 Med Tech & Life Sciences West Coast Field Trip 09/10/22 ESMO Congress 2022 EXAS Exact Sciences $39.56 / -1.54 (-3.75%) 08/02/22 EXACT Sciences options imply 7.0% move in share price post-earnings
Recommendations	Cytek Biosciences price target raised to $16 from $12 at Piper Sandler » 21:41 08/17/22 08/17 21:41 08/17/22 21:41 CTKB Cytek Biosciences / + Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on Cytek Biosciences to $16 from $12 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options CTKB Cytek Biosciences / + 05/24/22 Cytek Biosciences receives CE Marking for series of cFluor reagents, TBNK kit 04/28/22 Cytek Biosciences appoints Garland as CCO CTKB Cytek Biosciences / + 08/17/22 Piper Sandler Cytek Biosciences price target raised to $16 from $12 at Piper Sandler 07/19/22 Piper Sandler Cytek Biosciences is best value in cell analysis, says Piper Sandler 06/22/22 Piper Sandler Piper Sandler bullish on Cytek Biosciences following analyst day 05/15/22 Piper Sandler Cytek Biosciences price target lowered to $12 from $17 at Piper Sandler CTKB Cytek Biosciences / + 08/10/22 Cytek Biosciences sees FY22 revenue $160M-$168M, consensus $166.51M 08/10/22 Cytek Biosciences reports Q2 EPS 0c, consensus 2c 06/22/22 Cytek Biosciences sees 2022 revenue closer to high end of $160M-$168M view 05/11/22 Cytek Biosciences reports Q1 EBITDA $1.9M vs. $1.1M last year CTKB Cytek Biosciences / + 03/07/22 Fly Insider: B. Riley, Fortive among weeks notable insider trades CTKB Cytek Biosciences / + 06/08/22 Twelve new option listings and one option delisting on June 8th
Recommendations	Cytek Biosciences price target raised to $16 from $12 at Piper Sandler » 21:41 08/17/22 08/17 21:41 08/17/22 21:41 CTKB Cytek Biosciences $14.09 / -0.07 (-0.49%) Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on Cytek Biosciences to $16 from $12 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options CTKB Cytek Biosciences $14.09 / -0.07 (-0.49%) 05/24/22 Cytek Biosciences receives CE Marking for series of cFluor reagents, TBNK kit 04/28/22 Cytek Biosciences appoints Garland as CCO CTKB Cytek Biosciences $14.09 / -0.07 (-0.49%) 07/19/22 Piper Sandler Cytek Biosciences is best value in cell analysis, says Piper Sandler 06/22/22 Piper Sandler Piper Sandler bullish on Cytek Biosciences following analyst day 05/15/22 Piper Sandler Cytek Biosciences price target lowered to $12 from $17 at Piper Sandler 03/01/22 Piper Sandler Cytek Biosciences price target lowered to $17 from $20 at Piper Sandler CTKB Cytek Biosciences $14.09 / -0.07 (-0.49%) 08/10/22 Cytek Biosciences sees FY22 revenue $160M-$168M, consensus $166.51M 08/10/22 Cytek Biosciences reports Q2 EPS 0c, consensus 2c 06/22/22 Cytek Biosciences sees 2022 revenue closer to high end of $160M-$168M view 05/11/22 Cytek Biosciences reports Q1 EBITDA $1.9M vs. $1.1M last year CTKB Cytek Biosciences $14.09 / -0.07 (-0.49%) 03/07/22 Fly Insider: B. Riley, Fortive among weeks notable insider trades CTKB Cytek Biosciences $14.09 / -0.07 (-0.49%) 06/08/22 Twelve new option listings and one option delisting on June 8th
Recommendations	Akoya Biosciences price target raised to $17 from $14 at Piper Sandler » 21:41 08/17/22 08/17 21:41 08/17/22 21:41 AKYA Akoya Biosciences $13.35 / -0.64 (-4.57%) Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on Akoya Biosciences to $17 from $14 and keeps an Overweight rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings AKYA Akoya Biosciences $13.35 / -0.64 (-4.57%) 06/28/22 Akoya to partner with Acrivon Therapeutics to develop OncoSignature Test 06/01/22 Akoya Biosciences to highlight spacial transcriptomics capabilities at AGBT 05/05/22 Akoya BioSciences trading resumes 05/05/22 Akoya BioSciences trading halted, volatility trading pause AKYA Akoya Biosciences $13.35 / -0.64 (-4.57%) 06/22/22 BTIG Akoya Biosciences initiated with a Buy at BTIG 05/15/22 Piper Sandler Akoya Biosciences price target lowered to $14 from $18 at Piper Sandler 04/13/22 Piper Sandler Akoya not impacted from NanoString miss, says Piper Sandler 03/17/22 Piper Sandler Akoya Biosciences price target lowered to $18 from $23 at Piper Sandler AKYA Akoya Biosciences $13.35 / -0.64 (-4.57%) 08/08/22 Akoya Biosciences raises FY22 revenuev view to $71M-$74M, consensus $71.7M 08/08/22 Akoya Biosciences reports Q2 EPS (47c), consensus (37c) 05/05/22 Akoya Biosciences reports Q1 EPS (44c), consensus (39c) 03/14/22 Akoya Biosciences sees FY22 revenue $69M-$71M, consensus $69.99M
Recommendations	Adaptive Biotechnologies price target raised to $12 from $7.50 at Piper Sandler » 21:40 08/17/22 08/17 21:40 08/17/22 21:40 ADPT Adaptive Biotechnologies $11.55 / -0.345 (-2.90%) Piper Sandler analyst… Piper Sandler analyst David Westenberg raised the firm's price target on Adaptive Biotechnologies to $12 from $7.50 and keeps a Neutral rating on the shares. The analyst updated models in the genomic tools and labs space following earnings. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ADPT Adaptive Biotechnologies $11.55 / -0.345 (-2.90%) 07/28/22 Adaptive Biotechnologies receives expanded Medicare coverage of clonoSEQ 06/15/22 Adaptive Biotechnologies launches T-Detect Lyme 05/23/22 Cathie Wood's ARK Invest bought 399.7K shares of Adaptive Biotechnologies today 03/25/22 Adaptive Biotechnologies Chief Medical Officer, Lance Baldo, resigns ADPT Adaptive Biotechnologies $11.55 / -0.345 (-2.90%) 06/02/22 Piper Sandler Adaptive Biotechnologies initiated with a Neutral at Piper Sandler 02/16/22 BTIG Adaptive Biotechnologies price target lowered to $30 from $35 at BTIG 02/02/22 BTIG Adaptive Biotechnologies price target lowered to $35 from $45 at BTIG 01/11/22 BTIG Adaptive Biotechnologies price target lowered to $45 from $55 at BTIG ADPT Adaptive Biotechnologies $11.55 / -0.345 (-2.90%) 08/03/22 Adaptive Biotechnologiesbacks FY22 revenue $185M-$195M, consensus $187.62M 08/03/22 Adaptive Biotechnologies reports Q2 EPS (37c), consensus (43c) 05/04/22 Adaptive Biotechnologies backs FY22 revenue $185M-$195M, consensus $189.38M 05/04/22 Adaptive Biotechnologies reports Q1 EPS (44c), consensus (45c) ADPT Adaptive Biotechnologies $11.55 / -0.345 (-2.90%) 08/03/22 Fly Intel: After-Hours Movers 08/29/22 Med Tech & Life Sciences West Coast Field Trip

Hot Stocks	Hyzon Motors names Parker Meeks as interim CEO » 21:03 08/17/22 08/17 21:03 08/17/22 21:03 HYZN Hyzon Motors $2.29 / -0.065 (-2.77%) Hyzon Motors… Hyzon Motors "announced the company's Board of Directors has appointed Parker Meeks, most recently Hyzon's Chief Strategy Officer, as President and Interim CEO, effective immediately, replacing Craig Knight who is also departing from his role as a director of the Company. Mr. Meeks will assume full responsibility for day-to-day management of all business lines and functions reporting to the company's Board of Directors. The Board plans to initiate a search to identify potential external and internal candidates to serve as the Company's next CEO. Additionally, George Gu has transitioned from his executive role with the Company to the non-executive Chairman of the Board. In his role as non-executive Chairman, Mr. Gu will remain available to provide strategic counsel to Mr. Meeks specifically related to R&D initiatives." ShowHide Related Items >><< Company News Street Research Earnings On The Fly HYZN Hyzon Motors $2.29 / -0.065 (-2.77%) 08/17/22 Hyzon Motors receives late filing notice from Nasdaq 08/05/22 Hyzon: Holthausen deal not expected to close on terms originally agreed 08/05/22 Hyzon Motors appoints independent board members to investigate certain issues 08/05/22 Hyzon Motors withdraws all guidance issued for all periods HYZN Hyzon Motors $2.29 / -0.065 (-2.77%) 08/06/22 Goldman Sachs Goldman Sachs suspends Hyzon Motors rating amid board investigation 08/05/22 DA Davidson Hyzon Motors downgraded to Neutral from Buy at DA Davidson 08/05/22 Melius Research Hyzon Motors downgraded to Hold from Buy at Melius Research 08/05/22 Wedbush Hyzon Motors downgraded to Neutral from Outperform at Wedbush HYZN Hyzon Motors $2.29 / -0.065 (-2.77%) 05/06/22 Hyzon Motors reports Q1 EPS (3c), consensus (9c) 03/23/22 Hyzon Motors reports Q4 EPS (12c), consensus (12c) HYZN Hyzon Motors $2.29 / -0.065 (-2.77%) 08/05/22 What You Missed On Wall Street On Friday 08/05/22 What You Missed On Wall Street This Morning 08/05/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/05/22 Fly Intel: Pre-market Movers
Hot Stocks	SPDR Gold Shares holdings falls from 992.2MT to 989.0MT » 20:42 08/17/22 08/17 20:42 08/17/22 20:42 GLD SPDR Gold Shares $164.36 / -1.08 (-0.65%) This is the fourth… This is the fourth consecutive decrease and the lowest level of holdings in seven months. ShowHide Related Items >><< Company News Technical Analysis GLD SPDR Gold Shares $164.36 / -1.08 (-0.65%) 08/15/22 Greenlight Capital buys Rivian, exits Intel in Q2 08/15/22 Paulson buys VMware, exits DiDi in Q2 05/23/22 SPDR Gold Shares holdings rise from 1,063.4MT to 1,068.1MT 05/19/22 SPDR Gold Shares holdings rise from 1,049.2MT to 1,056.2MT GLD SPDR Gold Shares $164.36 / -1.08 (-0.65%) 04/22/22 On The Fly: ETF fund flow highlights 03/11/22 On The Fly: ETF fund flow highlights 03/04/22 On The Fly: ETF fund flow highlights 02/25/22 On The Fly: ETF fund flow highlights
Hot Stocks	Chewy CEO sells $11.26M in common stock » 20:31 08/17/22 08/17 20:31 08/17/22 20:31 CHWY Chewy $48.23 / -1.825 (-3.65%) In a regulatory filing,… In a regulatory filing, Chewy disclosed that its CEO Sumit Singh sold 228.4K shares of common stock on August 15 in a total transaction size of $11.26M. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options CHWY Chewy $48.23 / -1.825 (-3.65%) 08/04/22 Chewy announces expansion of Insurance and Wellness offering 06/08/22 Chewy director Star buys $5.0M in common stock 06/02/22 Chewy rises 20.1% 06/02/22 Chewy rises 15.2% CHWY Chewy $48.23 / -1.825 (-3.65%) 08/04/22 Canaccord Trupanion price target lowered to $90 from $100 at Canaccord 07/26/22 Wedbush Wedbush downgrades Chewy to Neutral, raises price target to $44 07/26/22 Wedbush Chewy downgraded to Neutral from Outperform at Wedbush 06/27/22 Needham Chewy upgraded to Buy from Hold at Needham CHWY Chewy $48.23 / -1.825 (-3.65%) 06/01/22 Chewy reports Q1 EPS 4c, consensus (14c) 06/01/22 Notable companies reporting after market close 03/29/22 Chewy sees FY22 revenue $10.2B-$10.4B, consensus $10.61B 03/29/22 Chewy sees Q1 revenue $2.40B-$2.43B, consensus $2.51B CHWY Chewy $48.23 / -1.825 (-3.65%) 05/28/22 Chewy earnings might not be so great but stock could take off, Barron's says 03/06/22 Chewy co-founder Ryan Cohen takes large stake in Bed Bath & Beyond, WSJ says CHWY Chewy $48.23 / -1.825 (-3.65%) 08/12/22 Short Report: Bed Bath Beyond shorts nudge higher as stock soars 07/26/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/11/22 Game On: Wedbush's Pachter calls GameStop chairman 'deluded' 06/27/22 What You Missed On Wall Street On Monday 08/30/22 Chewy - CHWY CHWY Chewy $48.23 / -1.825 (-3.65%) 07/26/22 Chewy put volume heavy and directionally bearish 07/14/22 Chewy put volume heavy and directionally bearish 07/13/22 Chewy put volume heavy and directionally bearish 07/08/22 Chewy put volume heavy and directionally bearish
Hot Stocks	Cathie Wood's ARK Investment bought 340K shares of Pacific Biosciences today 20:27 08/17/22 08/17 20:27 08/17/22 20:27 PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/16/22 Cathie Wood's ARK Investment bought 173.7K shares of Pacific Biosciences today 08/11/22 Pacific Biosciences trading resumes 08/11/22 Pacific Biosciences trading halted, volatility trading pause 08/04/22 Cathie Wood's ARK Investment bought 212K shares of Pacific Biosciences today PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/11/22 Piper Sandler Illumina miss 'surprising' given backlog, says Piper Sandler 08/04/22 Canaccord Pacific Biosciences price target lowered to $14 from $17 at Canaccord 05/15/22 Piper Sandler Pacific Biosciences price target lowered to $6 from $13 at Piper Sandler 05/05/22 Cantor Fitzgerald Pacific Biosciences price target lowered to $19 from $23 at Cantor Fitzgerald PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/03/22 Pacific Biosciences now sees 2022 revenue $138M-$145M, consensus $161.95M 08/03/22 Pacific Biosciences reports Q2 non-GAAP EPS (34c), consensus (32c) 05/04/22 Pacific Biosciences reports Q1 EPS (37c), consensus (31c) PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/04/22 What You Missed On Wall Street On Thursday 08/04/22 What You Missed On Wall Street This Morning 07/21/22 What You Missed On Wall Street This Morning 07/01/22 What You Missed On Wall Street On Friday 08/22/22 Pacific Biosciences - PACB 08/23/22 Pacific Biosciences PACB Pacific Biosciences $7.60 / -0.41 (-5.12%) 08/10/22 Pacific Biosciences call volume above normal and directionally bullish 08/03/22 Pacific Biosciences options imply 13.0% move in share price post-earnings 03/18/22 Pacific Biosciences call volume above normal and directionally bullish
Hot Stocks	Cathie Wood's ARK Investment bought 1.11M shares of Invitae today 20:26 08/17/22 08/17 20:26 08/17/22 20:26 NVTA Invitae $4.25 / -0.2 (-4.50%) ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options NVTA Invitae $4.25 / -0.2 (-4.50%) 08/15/22 Invitae rises 11.4% 08/12/22 Invitae rises 29.0% 08/12/22 Invitae rises 20.6% 08/11/22 Invitae falls -42.9% NVTA Invitae $4.25 / -0.2 (-4.50%) 08/10/22 JPMorgan Invitae cut to Underweight at JPMorgan with future growth yet to be proven 08/10/22 JPMorgan Invitae downgraded to Underweight from Neutral at JPMorgan 07/26/22 Cowen Invitae cut to Market Perform at Cowen on debt refinancing uncertainty 07/26/22 Cowen Invitae downgraded to Market Perform from Outperform at Cowen NVTA Invitae $4.25 / -0.2 (-4.50%) 08/09/22 Invitae backs FY22 revenue growth of low double digits, consensus $542.96M 08/09/22 Invitae reports Q2 adjusted EPS (68c), consensus (76c) 07/18/22 Invitae sees second half of FY22 revenue flat over first half of FY22 07/18/22 Invitae sees Q2 revenue $136M, consensus $142.74M NVTA Invitae $4.25 / -0.2 (-4.50%) 08/10/22 What You Missed On Wall Street On Wednesday 08/10/22 What You Missed On Wall Street This Morning 07/21/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/18/22 Fly Intel: After-Hours Movers 09/10/22 ESMO Congress 2022 NVTA Invitae $4.25 / -0.2 (-4.50%) 08/12/22 Unusually active option classes on open August 12th 08/11/22 Invitae call buyer realizes 3500% same-day gains 05/03/22 Invitae options imply 14.1% move in share price post-earnings 02/24/22 Invitae options imply 14.1% move in share price post-earnings
Hot Stocks	Cathie Wood's ARK Investment bought 311K shares of Teladoc today 20:25 08/17/22 08/17 20:25 08/17/22 20:25 TDOC Teladoc $35.93 / -3.51 (-8.90%) ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options TDOC Teladoc $35.93 / -3.51 (-8.90%) 08/11/22 Cathie Wood's ARK Investment bought 101K shares of Teladoc today 08/10/22 Teladoc Health makes A1C testing easier for members with diabetes 08/09/22 Cathie Wood's ARK Investment bought 129.8K shares of Teladoc today 08/08/22 Cathie Wood's ARK Investment bought 210K shares of Teladoc today TDOC Teladoc $35.93 / -3.51 (-8.90%) 08/17/22 Guggenheim Guggenheim cuts Teladoc to Sell with growth remaining pressured 08/17/22 Guggenheim Teladoc downgraded to Sell from Neutral at Guggenheim 08/11/22 DA Davidson Teladoc initiated with a Buy at DA Davidson 08/02/22 Berenberg Berenberg downgrades Teladoc to Hold on 'underwhelming execution' TDOC Teladoc $35.93 / -3.51 (-8.90%) 07/27/22 Teladoc cuts FY22 EPS view to ($62.00)-($61.00) from ($43.50)-($43.00) 07/27/22 Teladoc sees Q3 EPS (85c)-(60c), consensus (55c) 07/27/22 Teladoc reports Q2 EPS ($19.22), consensus (64c) 07/27/22 Notable companies reporting after market close TDOC Teladoc $35.93 / -3.51 (-8.90%) 05/07/22 Disrupters getting punished, old-school rivals the winners, Barron's says 03/08/22 Lawmakers considering extending telehealth policies, STATNews reports TDOC Teladoc $35.93 / -3.51 (-8.90%) 08/17/22 What You Missed On Wall Street On Wednesday 08/17/22 What You Missed On Wall Street This Morning 08/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/05/22 Sell these stocks now, proven algorithm says TDOC Teladoc $35.93 / -3.51 (-8.90%) 08/08/22 Teladoc call volume above normal and directionally bullish 07/27/22 Teladoc options imply 16.7% move in share price post-earnings 07/26/22 Teladoc put volume heavy and directionally bearish 07/06/22 Unusually active option classes on open July 6th
Earnings	Notable companies reporting before tomorrow's open » 20:25 08/17/22 08/17 20:25 08/17/22 20:25 EL Estee Lauder $276.80 / +0.63 (+0.23%) , BJ BJ's Wholesale $69.11 / -0.125 (-0.18%) , TPR Tapestry $37.12 / -0.025 (-0.07%) , KSS Kohl's $33.91 / -1.165 (-3.32%) Notable companies… Notable companies reporting before tomorrow's open, with earnings consensus, include Estee Lauder (EL), consensus 33c... BJ's Wholesale (BJ), consensus 80c... Tapestry (TPR), consensus 77c... Kohl's (KSS), consensus $1.03. ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options TPR KSS EL BJ TPR Tapestry $37.12 / -0.025 (-0.07%) 08/04/22 Tapestry COO Tom Glaser retires, Scott Roe to succeed 05/12/22 Tapestry rises 8.5% 05/12/22 Tapestry seeing pricing power across all brands 05/12/22 Tapestry expects Shanghai lockdown to be lifted in early June KSS Kohl's $33.91 / -1.165 (-3.32%) 08/15/22 David Tepper's Appaloosa buys Salesforce, exits Nordstrom in Q2 08/15/22 Kohl's appoints Christie Raymond as chief marketing officer 08/12/22 Starboard Value exits ZeroFox, boosts Mercury Systems in Q2 08/10/22 Kohl's expands self-pickup to all stores nationwide EL Estee Lauder $276.80 / +0.63 (+0.23%) 07/17/22 Fly Intel: Top five weekend stock stories 06/07/22 Estee Lauder strengthens fulfillment network with new distribution center 05/03/22 Estee Lauder falls -11.9% 05/03/22 Estee Lauder falls over 10% to $233.50 after Q3 earnings, FY22 guidance cut BJ BJ's Wholesale $69.11 / -0.125 (-0.18%) 06/10/22 BJ's Wholesale opens four new clubs in IN, OH, NJ, VA 05/18/22 BJ's Wholesale falls -16.0% 04/06/22 MamaMancini's secures new product placements with tier-1 retailers 03/30/22 BJ's Wholesale launches 'Same-Day Select' service EL BJ TPR KSS EL Estee Lauder $276.80 / +0.63 (+0.23%) 08/09/22 Deutsche Bank Estee Lauder price target lowered to $266 from $274 at Deutsche Bank 07/21/22 JPMorgan Estee Lauder price target lowered to $265 from $270 at JPMorgan 05/31/22 Oppenheimer Estee Lauder added back to Top Pick status at Oppenheimer 05/04/22 RBC Capital Estee Lauder price target lowered to $322 from $361 at RBC Capital BJ BJ's Wholesale $69.11 / -0.125 (-0.18%) 08/11/22 Deutsche Bank BJ's Wholesale price target raised to $81 from $74 at Deutsche Bank 08/09/22 JPMorgan BJ's Wholesale price target raised to $58 from $57 at JPMorgan 06/02/22 Jefferies Costco price target raised to $580 from $560 at Jefferies 06/02/22 Jefferies BJ's Wholesale price target raised to $72 from $69 at Jefferies TPR Tapestry $37.12 / -0.025 (-0.07%) 07/21/22 BTIG Tapestry price target lowered to $48 from $53 at BTIG 07/21/22 Goldman Sachs Tapestry price target lowered to $35 from $39 at Goldman Sachs 07/15/22 UBS Tapestry price target lowered to $31 from $36 at UBS 07/07/22 Wells Fargo Tapestry price target lowered to $40 from $45 at Wells Fargo KSS Kohl's $33.91 / -1.165 (-3.32%) 08/04/22 Cowen Kohl's downgraded to Market Perform on consumer pressure at Cowen 08/04/22 Cowen Kohl's downgraded to Market Perform from Outperform at Cowen 07/26/22 Deutsche Bank Walmart outlook 'red flag for apparel,' says Deutsche Bank 07/15/22 UBS Kohl's price target lowered to $20 from $32 at UBS TPR KSS EL BJ TPR Tapestry $37.12 / -0.025 (-0.07%) 05/12/22 Tapestry cuts FY22 EPS view to $3.45 from $3.60-$3.65, consensus $3.62 05/12/22 Tapestry reports Q3 non-GAAP EPS 51c, consensus 41c 05/11/22 Notable companies reporting before tomorrow's open KSS Kohl's $33.91 / -1.165 (-3.32%) 07/01/22 Kohl's cuts Q2 sales view to down high-single digits from down low-single digits 05/19/22 Kohl's cuts FY22 adjusted EPS view to $6.45-$6.85 from $7.00-$7.50 05/19/22 Kohl's reports Q1 adjusted EPS 11c, consensus 70c EL Estee Lauder $276.80 / +0.63 (+0.23%) 08/17/22 Notable companies reporting before tomorrow's open 05/03/22 Estee Lauder cuts FY22 EPS view to $7.05-$7.15 from $7.43-$7.58 05/03/22 Estee Lauder reports Q3 adjusted EPS $1.91, consensus $1.67 05/03/22 Estee Lauder reports Q3 EPS $1.53, consensus $1.67 BJ BJ's Wholesale $69.11 / -0.125 (-0.18%) 05/19/22 BJ's Wholesale sees 2022 EPS flat year-over-year, consensus $3.28 05/19/22 BJ's Wholesale reports Q1 adjusted EPS 87c, consensus 71c 05/18/22 Notable companies reporting before tomorrow's open KSS EL KSS Kohl's $33.91 / -1.165 (-3.32%) 07/01/22 Kohl's looking to sell some real estate, board chair tells CNBC 07/01/22 Kohl's looking to sell some real estate, CNBC reports 07/01/22 Kohl's terminates buyout talks with Franchise Group, CNBC reports 06/22/22 Franchise Group considers lowering Kohl's bid nearer to $50 per share, CNBC says EL Estee Lauder $276.80 / +0.63 (+0.23%) 08/01/22 Estee Lauder in talks to buy Tom Ford in potential $3B or more deal, WSJ says 07/16/22 Estee Lauder stock looking like a buy, Barron's says 07/01/22 Estee Lauder tells WWD Too Faced Tmall shutting down in China 03/08/22 Estee Lauder closing all stores in Russia, WSJ reports TPR KSS EL BJ TPR Tapestry $37.12 / -0.025 (-0.07%) 06/15/22 What You Missed On Wall Street On Wednesday 06/15/22 What You Missed On Wall Street This Morning 06/15/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 05/12/22 What You Missed On Wall Street On Thursday KSS Kohl's $33.91 / -1.165 (-3.32%) 08/04/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 07/07/22 What You Missed On Wall Street On Thursday 07/07/22 What You Missed On Wall Street This Morning 07/07/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations EL Estee Lauder $276.80 / +0.63 (+0.23%) 08/01/22 What You Missed On Wall Street On Monday 05/03/22 What You Missed On Wall Street On Tuesday 05/03/22 What You Missed On Wall Street This Morning 05/03/22 Fly Intel: Pre-market Movers BJ BJ's Wholesale $69.11 / -0.125 (-0.18%) 06/27/22 Fly Insider: American Woodmark, Coursera among week's notable insider trades 05/19/22 What You Missed On Wall Street On Thursday 05/19/22 What You Missed On Wall Street This Morning 05/19/22 Fly Intel: Pre-market Movers 08:00 Today Tapestry - TPR 08:30 Today BJ's Wholesale - BJ 09:00 Today Kohl's - KSS 09:30 Today Estee Lauder - EL TPR KSS EL BJ TPR Tapestry $37.12 / -0.025 (-0.07%) 05/12/22 Early notable gainers among liquid option names on May 12th 04/11/22 Tapestry call volume above normal and directionally bullish 04/08/22 Tapestry call volume above normal and directionally bullish KSS Kohl's $33.91 / -1.165 (-3.32%) 08/09/22 Kohl's put volume heavy and directionally bearish 07/20/22 Kohl's call volume above normal and directionally bullish 03/09/22 Call spread in Kohls likely adjusts recent trade EL Estee Lauder $276.80 / +0.63 (+0.23%) 05/27/22 Early notable gainers among liquid option names on May 27th BJ BJ's Wholesale $69.11 / -0.125 (-0.18%) 05/19/22 Unusually active option classes on open May 19th
Downgrade	Stronghold Digital Mining downgraded to Market Perform from Outperform at Cowen » 20:17 08/17/22 08/17 20:17 08/17/22 20:17 SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) Cowen analyst Stephen… Cowen analyst Stephen Glagola downgraded Stronghold Digital Mining to Market Perform from Outperform with a price target of $2.25, down from $11. The analyst cites the company's announced shift in the majority of its power generation to grid sales over the near term, downsizing to 1.4 EH/s amid a debt restructuring. Glagola warns that while this may be the best choice, the change also results in a sub-scale operator where management will have to establish credibility. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Options SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) 08/16/22 Stronghold Digital Mining mines 637 gross Bitcoin in Q2 08/11/22 Stronghold Digital Mining reschedules Q2 conference call 04/14/22 Stronghold Digital Mining appoints Matthew Smith to CFO SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) 08/17/22 B. Riley Stronghold Digital Mining price target lowered to $4 from $5 at B. Riley 07/26/22 B. Riley B. Riley adds Riot Blockchain to '25 for 2022' pick list, removes Stronghold 06/28/22 Compass Point Stronghold Digital Mining price target lowered to $8 from $16 at Compass Point 06/23/22 B. Riley Stronghold Digital Mining price target lowered to $5 from $13 at B. Riley SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) 08/16/22 Stronghold Digital Mining reports Q2 EPS (82c) vs. ($123.86) last year 05/16/22 Stronghold Digital Mining reports Q1 EPS (66c), consensus (2c) 03/29/22 Stronghold Digital Mining reports Q4 EPS (52c), consensus 4c 20 Oct SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) 06/10/22 EU near agreement on legislation to regulate cryptocurrency, Bloomberg says 03/14/22 EU crypto mining proposal fails in parliamentary panel vote, Bloomberg says SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) 06/10/22 What You Missed On Wall Street On Friday 04/14/22 Fly Intel: After-Hours Movers 03/30/22 What You Missed On Wall Street On Wednesday 03/30/22 What You Missed On Wall Street This Morning SDIG Stronghold Digital Mining $2.39 / -0.815 (-25.47%) 08/15/22 Stronghold Digital Mining options imply 19.4% move in share price post-earnings 08/01/22 Largest borrow rate increases among liquid names 03/29/22 Stronghold Digital Mining options imply 8.3% move in share price post-earnings
Hot Stocks	Newpark Resources director buys $239.5K in common stock » 19:03 08/17/22 08/17 19:03 08/17/22 19:03 NR Newpark Resources $2.64 / -0.02 (-0.75%) In a regulatory filing,… In a regulatory filing, Newpark Resources disclosed that its director Donald Young bought 89.6K shares of common stock on August 15th in a total transaction size of $239.5K. ShowHide Related Items >><< Company News NR Newpark Resources $2.64 / -0.02 (-0.75%) 02/18/22 Newpark Resources enters cooperation agreement with BLR, adds member to board
Hot Stocks	CI&T acquires Transpire for A$16.4M » 19:01 08/17/22 08/17 19:01 08/17/22 19:01 CINT CI&T $13.90 / +0.12 (+0.87%) CI&T announced the… CI&T announced the execution of a sale and purchase agreement to acquire Transpire Technology Pty Ltd, an Australian technology consultancy, to enhance its growth in APAC. The purchase price for the acquisition is A$23.4M, or $16.4M. Transpire recorded AUD15.5, or $10.9M, in net revenue in its fiscal year ended in June 2022. The completion of this transaction is subject to the satisfaction of customary closing conditions and is expected to happen during the third quarter of 2022. ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options CINT CI&T $13.90 / +0.12 (+0.87%) 08/16/22 CI&T acquires Transpire for $16.4M 06/01/22 CI&T acquires Box 1824, terms undisclosed 05/19/22 CI&T falls -10.9% 05/19/22 CI&T falls -14.6% CINT CI&T $13.90 / +0.12 (+0.87%) 07/20/22 JPMorgan CI&T price target lowered to $15 from $18 at JPMorgan 12/06/21 Fly Intel: Top five analyst initiations 12/06/21 BofA BofA starts 'IT services rare breed' CI&T with a Buy 12/06/21 Morgan Stanley Morgan Stanley starts CI&T at Overweight, sees shares trading at discount CINT CI&T $13.90 / +0.12 (+0.87%) 08/17/22 CI&T sees FY22 revenue growth of at least 55% on constant currency basis 08/17/22 3CI&T sees Q3 net revenue up at least 46% from Q322 to R$540M 08/17/22 CI&T reports Q2 up 67% y-o-y to R$525.0M 05/18/22 CI&T raises FY22 net revenue view to $442M from $433M, consensus $431.4M 10 Nov CINT CI&T $13.90 / +0.12 (+0.87%) 05/19/22 Fly Intel: Pre-market Movers 05/18/22 Fly Intel: After-Hours Movers 08:00 Today CI&T - CINT CINT CI&T $13.90 / +0.12 (+0.87%) 05/25/22 new option listings and one option delisting on May 25th

Hot Stocks	NYSE to suspend trading in Eros Media World » 18:46 08/17/22 08/17 18:46 08/17/22 18:46 EMWP Eros Media World $1.61 / -0.05 (-3.01%) NYSE announced that the… NYSE announced that the staff of NYSE Regulation has determined to commence proceedings to delist the A Ordinary Shares of Eros Media World Plc from the NYSE. Trading in the company's A Ordinary Shares will be suspended immediately. NYSE Regulation reached its decision that the company's A Ordinary Shares are not suitable for listing, because the company is a late filer and has not filed with the Securities and Exchange Commission its annual report on Form 20-F for the year ended March 31, 2021, current report on Form 6-K for the half year ended September 30, 2021 and annual report on Form 20-F for the year ended March 31, 2022. The company has a right to a review of this determination by a Committee of the Board of Directors of the Exchange.
Initiation	Casey's General Stores initiated with an Outperform at Wolfe Research » 18:30 08/17/22 08/17 18:30 08/17/22 18:30 CASY Casey's General Stores $212.86 / -0.16 (-0.08%) Wolfe Research analyst… Wolfe Research analyst Greg Badishkanian initiated coverage of Casey's General Stores with an Outperform rating and $228 price target. The analyst cites the company being in the early innings of consolidating the industry with "underappreciated opportunities" to expand margins and grow its EBITDA by high single digits within a defensive category. At 11-times expected FY23 EBITDA, the risk-reward on the stock appears to be favorable, Badishkanian tells investors in a research note. ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CASY Casey's General Stores $212.86 / -0.16 (-0.08%) 06/27/22 Casey's General Stores appoints Donthi to board of directors 06/07/22 Casey's General Stores sees FY23 same-store inside sales up 4%-6% 06/07/22 Casey's General Stores raises quarterly dividend 9% to 38c per share 04/21/22 Casey's General Stores provides business update ahead of NDR CASY Casey's General Stores $212.86 / -0.16 (-0.08%) 07/18/22 Benchmark Benchmark starts Casey's General Stores at Buy, cites proven growth model 07/18/22 Benchmark Casey's General Stores initiated with a Buy at Benchmark 06/22/22 Deutsche Bank Casey's General Stores price target lowered to $255 from $259 at Deutsche Bank 06/08/22 RBC Capital Casey's General Stores price target lowered to $238 from $250 at RBC Capital CASY Casey's General Stores $212.86 / -0.16 (-0.08%) 06/07/22 Casey's General Stores reports Q4 EPS $1.60, consensus $1.59 03/08/22 Casey's General Stores reports Q3 EPS $1.71, consensus $1.45 CASY Casey's General Stores $212.86 / -0.16 (-0.08%) 05/25/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 09/19/22 Groceryshop 09/08/22 Casey's General Stores - CASY 08/30/22 Casey's General Stores Inc.
Periodicals	WWE board finds former CEO McMahon gave $5M to Trump charity, WSJ says » 18:25 08/17/22 08/17 18:25 08/17/22 18:25 WWE WWE $71.86 / -1.41 (-1.92%) An internal board… An internal board investigation at World Wrestling Entertainment found that contributions totaling $5M to Donald Trump's charity in 2007 and 2009 were among the $19.6M in unrecorded expenses founder and former CEO Vince McMahon paid out before he left the company, the Wall Street Journal's Joe Palazzolo and Ted Man report. While the majority of the $19.6M in payments went to women who accused McMahon and another WWE executive of sexual misconduct, the company said previously in a regulatory filing that $5M was unrelated to such claims, the authors note. That particular amount represented charitable contributions to the now-dissolved Donald J. Trump Foundation in the same two years Trump made appearances at WWE televised events, the authors say, citing people familiar with the board investigation. Reference Link ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events WWE WWE $71.86 / -1.41 (-1.92%) 08/16/22 WWE announces record first-day ticket sales for WrestleMania 39 08/16/22 WWE raises FY22 adjusted OIBDA view to $370M-$385M from $360M-$375M 08/16/22 WWE sees Q3 adjusted OIBDA $70M-$80M 08/16/22 WWE: Probe of Vince McMahon 'substantially complete' WWE WWE $71.86 / -1.41 (-1.92%) 08/17/22 Benchmark WWE price target raised to $83 from $80 at Benchmark 08/17/22 Barclays Barclays ups WWE target but says company sale unlikely 07/26/22 Benchmark WWE price target raised to $80 from $71 at Benchmark 07/25/22 Loop Capital Loop Capital upgrades WWE to Buy on rising likelihood of company sale WWE WWE $71.86 / -1.41 (-1.92%) 08/16/22 WWE reports Q2 adjusted EPS 59c vs. 34c last year 07/25/22 WWE reports preliminary Q2 revenue $328M, consensus $311.84M 05/05/22 WWE sees Q2 adjusted OIBDA $80M-$90M 05/05/22 WWE reports Q1 EPS 77c, consensus 61c WWE WWE $71.86 / -1.41 (-1.92%) 07/08/22 WWE's Vince McMahon paid over $12M to suppress misconduct claims, WSJ says 07/01/22 WWE signs multi-event agreement with Logan Paul, ESPN reports 06/15/22 WWE board investigating $3M 'hush pact' settlement by CEO, WSJ says 04/07/22 Formula 1, WWE could be acquisition targets for streaming companies, CNBC says WWE WWE $71.86 / -1.41 (-1.92%) 08/16/22 What You Missed On Wall Street On Tuesday 08/16/22 What You Missed On Wall Street This Morning 07/25/22 What You Missed On Wall Street On Monday 07/25/22 What You Missed On Wall Street This Morning 09/08/22 Consumer/Media/Entertainment Conference
Earnings	America's Car-Mart reports Q1 EPS $2.00, consensus $3.14 » 18:20 08/17/22 08/17 18:20 08/17/22 18:20 CRMT America's Car-Mart $119.28 / -6.68 (-5.30%) Reports Q1 revenue… Reports Q1 revenue $344.82M, consensus $322.4M. "For the quarter, unit sales volumes were up 2.1% to 15,536 with productivity (retail units sold per dealership per month) flat at 33.6, versus 1Q22. Even with significant industry headwinds, namely higher vehicles prices resulting from supply/demand imbalances, especially at lower price points, we saw unit volumes increase...," said CEO Jeff Williams. "Revenues were up 23% to $345M, our second highest revenue quarter in history, with 4Q22 being first. We are seeing car prices level off and we expect a gradual flattening as we move forward - better news for consumers. Overall industry credit results are normalizing, and we are seeing customers coming into our market as lending standards tighten above us. Net charge-offs as a percentage of average receivables, were 5.6% for the quarter, flat sequentially and up from 4.3% for the prior year quarter. The prior year quarter was positively affected by stimulus payments and the current quarter was negatively affected by inflationary factors," said Mr. Williams. "Net charge-off results for the quarter were in line with our prior 5-year average and below the prior 10-year average. Once again, inflation is presenting challenges; however, our customers are benefiting from a robust job market, helping to somewhat offset these pressures. As vehicle prices level off, affordability and resulting sales volume opportunities should improve." ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events CRMT America's Car-Mart $119.28 / -6.68 (-5.30%) 03/16/22 America's Car-Mart appoints Brian Stone as EVP, procurement, inventory CRMT America's Car-Mart $119.28 / -6.68 (-5.30%) 04/06/22 BofA America's Car-Mart double-downgraded to Underperform at BofA 04/06/22 BofA America's Car-Mart downgraded to Underperform from Buy at BofA CRMT America's Car-Mart $119.28 / -6.68 (-5.30%) 05/23/22 America's Car-Mart reports Q4 EPS $4.01, consensus $3.10 CRMT America's Car-Mart $119.28 / -6.68 (-5.30%) 04/06/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 11:00 Today America's Car-Mart - CRMT 08/30/22 America's Car Mart Inc.
On The Fly	Fly Intel: After-Hours Movers » 18:16 08/17/22 08/17 18:16 08/17/22 18:16 WOLF Wolfspeed $85.58 / -3.08 (-3.47%) , CSCO Cisco $46.69 / -0.09 (-0.19%) , KEYS Keysight Technologies $169.27 / -1.45 (-0.85%) , SNPS Synopsys $380.78 / -4.86 (-1.26%) , BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) , DCP DCP Midstream $34.75 / -1.275 (-3.54%) , BBWI Bath & Body Works $40.39 / -0.63 (-1.54%) , AXDX Accelerate Diagnostics $3.38 / +0.165 (+5.14%) , QUIK QuickLogic $7.64 / -0.46 (-5.68%) , BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) , GME GameStop $40.58 / -1.57 (-3.72%) , APRN Blue Apron $5.70 / +0.315 (+5.85%) , FUBO FuboTV $5.36 / -1.005 (-15.80%) , AMC AMC Entertainment $21.36 / -3.45 (-13.91%) … Open Full Text ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options WOLF SNPS QUIK KEYS GME FUBO DCP CSCO BLUE BBWI BBBY AXDX APRN AMC WOLF Wolfspeed $85.58 / -3.08 (-3.47%) 08/17/22 Wolfspeed sees 2026 revenue outlook up 30%-40% from prior forecast 08/17/22 Wolfspeed jumps 12% to $95.59 after above-consensus Q4 earnings and guidance 05/09/22 Wolfspeed, Rhombus Energy collaborate for faster EV charging infrastructure 04/25/22 Wolfspeed says Lucid integrates Silicon Carbide solutions into Lucid Air SNPS Synopsys $380.78 / -4.86 (-1.26%) 06/22/22 Synopsys sees WhiteHat Security acquisition neutral to FY22 adjusted EPS 05/27/22 Synopsys initiates $200M ASR with Wells Fargo 05/24/22 Synopsys enters distribution agreement with Arrow Electronics QUIK QuickLogic $7.64 / -0.46 (-5.68%) 06/01/22 QuickLogic awarded new $3.0M eFPGA contract 03/30/22 QuickLogic wins new $1.5M eFPGA contract 03/10/22 QuickLogic wins new eFPGA contract for approximately $1M KEYS Keysight Technologies $169.27 / -1.45 (-0.85%) 08/15/22 Keysight Technologies extends collaboration with Synopsys 08/03/22 Keysight, Nokia collaborate on public 800GE test 07/29/22 The Digital IF Interoperability Consortium announces seven new members 07/13/22 AI-LINK selects Keysight's 5G test tools for performance validation GME GameStop $40.58 / -1.57 (-3.72%) 08/16/22 GameStop trading resumes 08/16/22 GameStop trading halted, volatility trading pause 08/08/22 GameStop trading resumes FUBO FuboTV $5.36 / -1.005 (-15.80%) 08/16/22 FuboTV rises 20.1% 08/11/22 FuboTV adds SportsGrid network 08/08/22 FuboTV rises 14.1% DCP DCP Midstream $34.75 / -1.275 (-3.54%) 08/17/22 Phillips 66 proposing consideration of $34.75 per unit of DCP Midstream 08/17/22 Phillips 66 increases interest in DCP Midstream from 28.26% to 43.31% 08/01/22 DCP Midstream releases annual Sustainability Report 07/19/22 DCP Midstream raises Q2 cash distribution 10% to 43c per unit CSCO Cisco $46.69 / -0.09 (-0.19%) 08/17/22 Cisco expects continued high levels of order backlog 08/17/22 Cisco says cancellations below pre-pandemic levels 08/17/22 Cisco sees Q1 adjusted gross margin 63%-64% 08/17/22 Cisco CEO says full year product orders, backlog at 'record highs' BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) 08/17/22 Bluebird Bio confirms Zynteglo wholesale acquisition cost of $2.8M 08/17/22 Bluebird Bio trading resumes 08/17/22 Bluebird Bio to resume trading at 2:30 pm ET 08/17/22 Bluebird Bio confirms FDA approval of Zynteglo BBWI Bath & Body Works $40.39 / -0.63 (-1.54%) 08/17/22 Bath & Body Works saw declines in traffic trends in June, first part of July 08/17/22 Bath & Body Works recently cut 130 roles in home office organization 05/19/22 Bath & Body Works sees FY inflation impact $225M-$250M 05/19/22 Bath & Body Works to test new personal care line, including face and hair care BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) 08/17/22 Meme stocks slip afterhours as Ryan Cohen files intent to cash out of BBBY 08/17/22 RC Ventures files to sell Bed Bath & Beyond stake 08/17/22 Bed Bath & Beyond trading resumes 08/17/22 Bed Bath & Beyond trading halted, volatility trading pause AXDX Accelerate Diagnostics $3.38 / +0.165 (+5.14%) 07/11/22 Accelerate Diagnostics announces commercialization in Europe of Accelerate Arc 05/16/22 Accelerate Diagnostics begins commercialization of Accelerate Arc system 04/25/22 Accelerate Diagnostics' Arc System kit shows sample accuracy in studies APRN Blue Apron $5.70 / +0.315 (+5.85%) 08/17/22 Blue Apron rises 10.6% 08/17/22 Blue Apron rises 22.5% 08/17/22 Blue Apron up 24% at $6.67 in pre-market trading AMC AMC Entertainment $21.36 / -3.45 (-13.91%) 08/17/22 Cineworld evaluates strategic options amid slow attendance, limited film slate 08/08/22 AMC Entertainment rises 16.9% 08/08/22 AMC Entertainment trading resumes 08/08/22 AMC Entertainment trading halted, volatility trading pause WOLF CSCO KEYS SNPS BLUE DCP BBWI AXDX QUIK BBBY GME APRN FUBO AMC WOLF Wolfspeed $85.58 / -3.08 (-3.47%) 08/15/22 Piper Sandler ON Semiconductor price target raised to $90 from $75 at Piper Sandler 07/14/22 JPMorgan Wolfspeed price target lowered to $80 from $105 at JPMorgan 06/29/22 BofA Wolfspeed price target lowered to $75 from $95 at BofA 06/23/22 Goldman Sachs Wolfspeed upgraded to Buy from Neutral at Goldman Sachs CSCO Cisco $46.69 / -0.09 (-0.19%) 08/15/22 Citi Cisco to trade lower due to valuation multiple compression, says Citi 08/02/22 Citi Arista Networks price target raised to $170 from $160 at Citi 07/15/22 KGI Securities Cisco downgraded to Neutral from Outperform at KGI Securities 07/14/22 JPMorgan Cisco downgraded to Neutral from Overweight at JPMorgan KEYS Keysight Technologies $169.27 / -1.45 (-0.85%) 08/09/22 Deutsche Bank Keysight Technologies price target raised to $190 from $176 at Deutsche Bank 07/14/22 JPMorgan Keysight Technologies price target lowered to $176 from $200 at JPMorgan 06/17/22 UBS Keysight Technologies price target lowered to $177 from $220 at UBS 06/01/22 Goldman Sachs Keysight Technologies price target lowered to $165 from $185 at Goldman Sachs SNPS Synopsys $380.78 / -4.86 (-1.26%) 08/16/22 Wolfe Research Synopsys initiated with an Outperform at Wolfe Research 08/11/22 Wells Fargo Synopsys price target raised to $425 from $375 at Wells Fargo 06/29/22 BofA Synopsys upgraded to Neutral from Underperform at BofA 05/19/22 Needham Synopsys price target raised to $380 from $370 at Needham BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) 08/17/22 BTIG Bluebird's approval has positive read for Mustang Bio, says BTIG 08/17/22 Piper Sandler Piper says FDA nod for Bluebird's beta-cel positive for Crispr's exa-cel 08/05/22 Barclays Barclays upgrades Bluebird Bio to Equal Weight, raises price target to $5 08/05/22 Barclays Bluebird Bio upgraded to Equal Weight from Underweight at Barclays DCP DCP Midstream $34.75 / -1.275 (-3.54%) 08/16/22 Barclays DCP Midstream price target raised to $40 from $38 at Barclays 07/20/22 Barclays DCP Midstream price target lowered to $38 from $43 at Barclays 07/12/22 RBC Capital DCP Midstream upgraded to Outperform from Sector Perform at RBC Capital 06/13/22 Raymond James DCP Midstream added to Analyst Current Favorites list at Raymond James BBWI Bath & Body Works $40.39 / -0.63 (-1.54%) 08/16/22 B. Riley Bath & Body Works price target raised to $48 from $44 at B. Riley 07/25/22 Barclays Bath & Body Works price target lowered to $33 from $40 at Barclays 07/21/22 Deutsche Bank Bath & Body Works price target lowered to $41 from $61 at Deutsche Bank 07/21/22 B. Riley Bath & Body risk/reward attractive despite guidance cut, says B. Riley AXDX Accelerate Diagnostics $3.38 / +0.165 (+5.14%) 03/09/22 Craig-Hallum Craig-Hallum downgrades Accelerate Diagnostics to Hold, lowers target to $5 03/09/22 Craig-Hallum Accelerate Diagnostics downgraded to Hold from Buy at Craig-Hallum 01/14/22 Craig-Hallum Accelerate Diagnostics price target lowered to $9 from $12 at Craig-Hallum QUIK QuickLogic $7.64 / -0.46 (-5.68%) 11/18/21 Roth Capital QuickLogic price target raised to $12 from $8 at Roth Capital BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) 08/16/22 Odeon Capital Odeon Capital downgrades Bed Bath & Beyond to Sell with $7.50 price target 08/16/22 Odeon Capital Bed Bath & Beyond downgraded to Sell from Hold at Odeon Capital 08/16/22 B. Riley B. Riley downgrades 'meme stock' Bed Bath & Beyond to Sell 08/16/22 B. Riley Bed Bath & Beyond downgraded to Sell from Neutral at B. Riley GME GameStop $40.58 / -1.57 (-3.72%) 07/22/22 Wedbush GameStop price target lowered to $7.50 from $30 at Wedbush 05/26/22 Wedbush Wedbush keeps Underperform on GameStop citing valuation and cash burn concerns 03/28/22 B. Riley Bed Bath & Beyond price target raised to $26 from $19 at B. Riley APRN Blue Apron $5.70 / +0.315 (+5.85%) 08/10/22 Lake Street Blue Apron initiated with a Buy at Lake Street 07/20/22 Benchmark Benchmark starts Blue Apron at Buy with turnaround not getting credit 07/20/22 Benchmark Blue Apron initiated with a Buy at Benchmark 05/10/22 Canaccord Blue Apron price target lowered to $10 from $12 at Canaccord FUBO FuboTV $5.36 / -1.005 (-15.80%) 08/17/22 Evercore ISI FuboTV price target raised to $8 from $5 at Evercore ISI 08/17/22 Stephens Stephens sees no major news from FuboTV analyst day to justify 'short squeeze' 08/17/22 Wedbush Wedbush downgrades FuboTV to Neutral, raises price target to $6 08/17/22 Wedbush FuboTV downgraded to Neutral from Outperform at Wedbush AMC AMC Entertainment $21.36 / -3.45 (-13.91%) 07/07/22 Citi AMC Entertainment price target lowered to $5 from $6 at Citi 06/21/22 B. Riley AMC Entertainment price target lowered to $11 from $16 at B. Riley 06/06/22 Citi AMC Entertainment shares remain overvalued, says Citi WOLF SNPS QUIK KEYS GME FUBO DCP CSCO BLUE BBWI BBBY AXDX APRN AMC WOLF Wolfspeed $85.58 / -3.08 (-3.47%) 08/17/22 Wolfspeed sees Q1 EPS (8c) to (2c), consensus (7c) 08/17/22 Wolfspeed reports Q4 EPS (2c), consensus (10c) 05/04/22 Wolfspeed sees Q4 adjusted EPS (13c)-(7c), consensus (12c) 05/04/22 Wolfspeed reports Q3 adjusted EPS (12c), consensus (14c) SNPS Synopsys $380.78 / -4.86 (-1.26%) 08/17/22 Synopsys sees Q4 non-GAAP EPS $1.06-$1.18, consensus $1.73 08/17/22 Synopsys raises FY22 non-GAAP EPS view to $8.80-$8.85 from $7.85-$7.92 08/17/22 Synopsys reports Q3 non-GAAP EPS $2.10 vs $1.81 a year ago QUIK QuickLogic $7.64 / -0.46 (-5.68%) 08/16/22 QuickLogic reports Q2 non-GAAP EPS 0c, consensus (4c) 06/01/22 QuickLogic backs Q2 revenue view $4.5M, consensus $4.47M 05/17/22 QuickLogic reports Q1 adjusted EPS (6c), consensus (7c) KEYS Keysight Technologies $169.27 / -1.45 (-0.85%) 08/17/22 Keysight Technologies sees Q4 adjusted EPS $1.94-$2.00, consensus $1.89 08/17/22 Keysight Technologies reports Q3 adjusted EPS $2.01, consensus $1.78 05/17/22 Keysight Technologies sees FY22 EPS up 14%-15%, consensus $7.01 05/17/22 Keysight Technologies sees Q3 EPS $1.74-$1.80, consensus $1.75 GME GameStop $40.58 / -1.57 (-3.72%) 06/01/22 GameStop reports Q1 EPS ($2.08), consensus ($1.45) 06/01/22 Notable companies reporting after market close 03/17/22 GameStop reports Q4 EPS ($1.94) vs $1.19 last year 03/17/22 Notable companies reporting after market close FUBO FuboTV $5.36 / -1.005 (-15.80%) 08/04/22 FuboTV reports Q2 EPS (45c), consensus (69c) 05/05/22 FuboTV reports Q1 EPS (69c), consensus (65c) 05/05/22 Notable companies reporting after market close 02/23/22 FuboTV reports Q4 EPS (57c), consensus (67c) DCP DCP Midstream $34.75 / -1.275 (-3.54%) 08/02/22 DCP Midstream reports Q2 EPS $1.77, consensus $1.13 05/04/22 DCP Midstream reports Q1 EPS 32c, may not compare to consensus 99c CSCO Cisco $46.69 / -0.09 (-0.19%) 08/17/22 Cisco sees FY23 adjusted EPS $3.49-$3.56, consensus $3.53 08/17/22 Cisco sees Q1 adjusted EPS 82c-84c, consensus 84c 08/17/22 Cisco reports Q4 adjusted EPS 83c, consensus 82c 08/17/22 Notable companies reporting after market close BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) 08/04/22 Bluebird Bio reports Q2 EPS ($1.36), consensus ($1.24) 05/09/22 Bluebird Bio reports Q1 EPS ($1.66), consensus ($1.39) 03/04/22 Bluebird Bio reports Q4 EPS ($2.14), consensus ($1.88) BBWI Bath & Body Works $40.39 / -0.63 (-1.54%) 08/17/22 Bath & Body Works sees FY revenue down mid to high single digits vs. last year 08/17/22 Bath & Body Works sees Q3 sales down mid to high single digits vs. last year 08/17/22 Bath & Body Works sees FY22 EPS $2.70-$3.00, consensus $2.92 08/17/22 Bath & Body Works sees Q3 EPS 10c-20c, consensus 31c BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) 06/29/22 Bed Bath & Beyond reports Q1 adjusted EPS ($2.83), consensus ($1.39) 06/28/22 Notable companies reporting before tomorrow's open 04/13/22 Bed Bath & Beyond reports Q4 adjusted EPS (92c), consensus 3c AXDX Accelerate Diagnostics $3.38 / +0.165 (+5.14%) 05/16/22 Accelerate Diagnostics reports Q1 EPS (21c), consensus (30c) 03/08/22 Accelerate Diagnostics reports Q4 adjusted EPS (23c), consensus (25c) APRN Blue Apron $5.70 / +0.315 (+5.85%) 08/08/22 Blue Apron cuts FY22 revenue growth view to 7%-13% vs. mid-teens 08/08/22 Blue Apron reports Q2 EPS (68c) vs. (98c) a year ago 05/10/22 Blue Apron targets revenue of $700M-plus in 2024 05/09/22 Blue Apron sees FY revenue growth in mid teens, one est. $532.3M AMC AMC Entertainment $21.36 / -3.45 (-13.91%) 08/04/22 AMC Entertainment reports Q2 adjusted EPS (20c), consensus (19c) 05/09/22 AMC Entertainment reports Q1 adjusted EPS (52c), consensus (63c) 05/09/22 Notable companies reporting after market close 05/05/22 Hycroft Mining reports Q1 EPS (27c) vs. (16c) last year SNPS GME CSCO BLUE BBBY APRN AMC SNPS Synopsys $380.78 / -4.86 (-1.26%) 04/13/22 Synopsys probed by Commerce Department over China, Bloomberg reports 04/13/22 Synopsys sent subpoena from Commerce Department on China, Blomberg says GME GameStop $40.58 / -1.57 (-3.72%) 08/13/22 Coinbase looking more like a meme stock, Barron's says 07/21/22 Europe game sales rose 13.5% year-over-year in 1H22, Gamesindustry.biz says 07/07/22 GameStop CFO Mike Recupero replaced by Diana Jajeh, Axios says 07/07/22 GameStop CFO out, company making layoffs, Axios says CSCO Cisco $46.69 / -0.09 (-0.19%) 06/23/22 Cisco, Nike planning to fully exit Russia, Reuters reports 06/23/22 Cisco to begin 'orderly wind-down' of Russia business, Reuters reports 06/06/22 CFOs send letter to Treasury Secretary on foreign tax credit rules, WSJ reports BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) 08/17/22 Bluebird Bio to charge $2.8M for Zynteglo treatment, Bloomberg says 06/10/22 FDA votes 13-0 in support of Bluebird Bio's Beti-Cel, Bloomberg reports 06/09/22 FDA panel: Bluebird Bio's Eli-Cel benefits outweigh risks, BioPharmaDrive says BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) 08/17/22 RC Ventures files to sell entire Bed Bath & Beyond stake, Bloomberg says 08/13/22 Royal Caribbean among companies at risk of liquidity squeeze, Barron's says 08/03/22 Bed Bath & Beyond weighing private loans, Bloomberg reports 08/03/22 Bed Bath & Beyond in talks with private credit providers, Bloomberg says APRN Blue Apron $5.70 / +0.315 (+5.85%) 05/10/22 Blue Apron shares going to $10 unless management 'sociopaths,' Citrons says AMC AMC Entertainment $21.36 / -3.45 (-13.91%) 08/15/22 Summer movies show audiences, studio chiefs committed to theaters, WSJ reports 07/11/22 U.S. box office sales rising closer to pre-pandemic levels, CNBC reports WOLF SNPS QUIK KEYS GME FUBO CSCO BLUE BBWI BBBY APRN AMC WOLF Wolfspeed $85.58 / -3.08 (-3.47%) 07/22/22 Sell these stocks now, proven algorithm says 07/15/22 Sell these stocks now, proven algorithm says 07/08/22 Sell these stocks now, proven algorithm says 06/24/22 What You Missed On Wall Street On Friday SNPS Synopsys $380.78 / -4.86 (-1.26%) 05/19/22 Fly Intel: Pre-market Movers 05/18/22 Fly Intel: After-Hours Movers 04/13/22 What You Missed On Wall Street On Wednesday QUIK QuickLogic $7.64 / -0.46 (-5.68%) 05/17/22 Fly Intel: After-Hours Movers KEYS Keysight Technologies $169.27 / -1.45 (-0.85%) 03/11/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations GME GameStop $40.58 / -1.57 (-3.72%) 08/12/22 Short Report: Bed Bath Beyond shorts nudge higher as stock soars 08/09/22 What You Missed This Week in Video Games 08/06/22 Opening Day: Magic Empire opening surge calls to mind AMTD Digital frenzy 08/03/22 Citron says AMTD Digital ‘NOT a meme stock’ despite massive rise in shares FUBO FuboTV $5.36 / -1.005 (-15.80%) 08/17/22 What You Missed On Wall Street This Morning 08/17/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 08/12/22 Bet On It: Massachusetts betting bill signed into law ahead of NFL season 05/13/22 Short Report: Upstart shorts take profits as stock craters on guidance cut CSCO Cisco $46.69 / -0.09 (-0.19%) 08/17/22 Here's what Wall Street experts are saying about Cisco ahead of earnings 06/23/22 What You Missed On Wall Street On Thursday 06/23/22 What You Missed On Wall Street This Morning 05/19/22 What You Missed On Wall Street On Thursday BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) 08/17/22 What You Missed On Wall Street On Wednesday 08/02/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/13/22 What You Missed On Wall Street On Monday 06/13/22 Fly Intel: Pre-market Movers BBWI Bath & Body Works $40.39 / -0.63 (-1.54%) 07/20/22 What You Missed On Wall Street On Wednesday 07/20/22 What You Missed On Wall Street This Morning 07/20/22 Fly Intel: Pre-market Movers 06/30/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) 08/16/22 Fly Intel: After-Hours Movers 08/16/22 What You Missed On Wall Street On Tuesday 08/16/22 What You Missed On Wall Street This Morning 08/16/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations APRN Blue Apron $5.70 / +0.315 (+5.85%) 08/10/22 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/04/22 Short Report: GameStop short position reaches 15-month high 06/01/22 Fly Intel: After-Hours Movers AMC AMC Entertainment $21.36 / -3.45 (-13.91%) 08/15/22 What You Missed On Wall Street This Morning 08/05/22 Fly Intel: Pre-market Movers 08/04/22 Fly Intel: After-Hours Movers 08/17/22 August Virtual Micro Cap Conference 08/17/22 Cisco - CSCO 08/17/22 Keysight Technologies - KEYS 08/17/22 Synopsys - SNPS 08/17/22 Wolfspeed - WOLF 09:00 Today Bath & Body Works - BBWI 09/23/22 Wolfspeed - WOLF 08/19/22 PDUFA Date for betibeglogene autotemcel (beti-cel) 09/16/22 PDUFA Date for Elivaldogene Autotemcel (Eli-cel, Lenti-D) WOLF SNPS GME FUBO CSCO BLUE BBWI BBBY APRN AMC WOLF Wolfspeed $85.58 / -3.08 (-3.47%) 08/17/22 Wolfspeed options imply 9.5% move in share price post-earnings SNPS Synopsys $380.78 / -4.86 (-1.26%) 08/17/22 Synopsys options imply 4.0% move in share price post-earnings 05/19/22 Early notable gainers among liquid option names on May 19th GME GameStop $40.58 / -1.57 (-3.72%) 08/16/22 GameStop call volume above normal and directionally bullish 08/08/22 GameStop call volume above normal and directionally bullish 07/25/22 Notable open interest changes for July 25th 07/22/22 Unusually active option classes on open July 22nd FUBO FuboTV $5.36 / -1.005 (-15.80%) 08/16/22 fuboTV call volume above normal and directionally bullish 08/03/22 Unusually active option classes on open August 3rd 07/15/22 Largest borrow rate increases among liquid names CSCO Cisco $46.69 / -0.09 (-0.19%) 08/17/22 Cisco options imply 4.7% move in share price post-earnings 06/28/22 Cisco put volume heavy and directionally bearish 06/10/22 Cisco put volume heavy and directionally bearish 05/20/22 Notable open interest changes for May 20th BLUE Bluebird Bio $6.78 / +0.195 (+2.96%) 08/12/22 Bluebird Bio call volume above normal and directionally bullish 08/11/22 Bluebird Bio call volume above normal and directionally bullish 08/08/22 Bluebird Bio call volume above normal and directionally bullish 08/05/22 Bluebird Bio call volume above normal and directionally bullish BBWI Bath & Body Works $40.39 / -0.63 (-1.54%) 08/17/22 Bath & Body Works options imply 7.3% move in share price post-earnings 08/16/22 Early notable gainers among liquid option names on August 16th 07/20/22 Bath & Body Works put volume heavy and directionally bearish 07/06/22 Bath & Body Works put volume heavy and directionally bearish BBBY Bed Bath & Beyond $22.98 / +2.24 (+10.80%) 08/17/22 Notable open interest changes for August 17th 08/16/22 Bed Bath & Beyond call volume above normal and directionally bullish 08/16/22 Notable open interest changes for August 16th 08/15/22 Unusually active option classes on open August 15th APRN Blue Apron $5.70 / +0.315 (+5.85%) 08/17/22 Unusually active option classes on open August 17th 08/16/22 Blue Apron call volume above normal and directionally bullish 07/07/22 Largest borrow rate increases among liquid names AMC AMC Entertainment $21.36 / -3.45 (-13.91%) 08/09/22 Notable open interest changes for August 9th 08/08/22 Notable open interest changes for August 8th 08/05/22 Notable open interest changes for August 5th 08/04/22 AMC Entertainment options imply 11.7% move in share price post-earnings

Events

Earnings calls, analyst events, roadshows and more

DAO
Today at 06:00

Youdao - DAO Conference Calls
STG
Today at 07:30

Sunlands Online - STG Conference Calls
CINT
Today at 08:00

CI&T - CINT Conference Calls
LMDX
Today at 08:00

LumiraDx - LMDX Conference Calls
CSIQ
Today at 08:00

Canadian Solar - CSIQ Conference Calls
JFIN
Today at 08:00

Jiayin Group - JFIN Conference Calls
NTES
Today at 08:00

NetEase - NTES Conference Calls
GRIN
Today at 08:00

Grindrod Shipping - GRIN Conference Calls
TPR
Today at 08:00

Tapestry - TPR Conference Calls
CAN
Today at 08:00

Canaan - CAN Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	BROS X BROS Dutch Bros Block Trade Managers: Morgan Stanley Priced at: $43.50 5.97M Shares GRFX X GRFX Graphex Group IPO Managers: EF Hutton Priced at: $2.50 4.7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial LUCY X LUCY Innovative Eyewear IPO Managers: Maxim Priced at: $7.50 980K Shares SVFD X SVFD Save Foods Secondary Managers: ThinkEquity Priced at: $3.00 1.6M Shares FULC X FULC Fulcrum Therapeutics Spot Secondary Managers: Goldman Sachs & SVB Securities, Stifel, Oppenheimer Priced at: $7.82 9.591M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial TELA X TELA Tela Bio Spot Secondary Managers: Lake Street Priced at: $8.00 4M Shares TRIN X TRIN Trinity Capital Spot Secondary Managers: Keefe Bruyette, Morgan Stanley, UBS & Wells Fargo Priced at: $15.33 3.6M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Tues	BE X BE Bloom Energy Secondary Managers: JPMorgan, Morgan Stanley & BofA Priced at: $26.00 13M Shares VRDN X VRDN Viridian Therapeutics Secondary Managers: Jefferies, SVB Securities & Evercore ISI Priced at: $23.50 9.628M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial ASLE X ASLE AerSale Spot Secondary Managers: Cowen, RBC Capital & Stifel, Truist Priced at: $17.25 4.25M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial OPCH X OPCH Option Care Health Spot Secondary Managers: Goldman Sachs Priced at: $33.25 11M Shares OSH X OSH Oak Street Health Spot Secondary Managers: JPMorgan, Goldman Sachs, Morgan Stanley, William Blair & Piper Sandler Priced at: $25.75 7M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	GFRX X GFRX Graphex Group Secondary Managers: EF Hutton Priced at: $2.50 4.7M Shares
Thurs	No deals
Fri	No deals

Mon	DVAX X DVAX Dynavax Block Trade Managers: Goldman Sachs $14.85-15.62 3M Shares
Tues	No deals
Wed	UBX X UBX Unity Biotechnology Secondary Managers: SVB Securities, Cantor Fitzgerald & MIZU, Wedbush $1.37 Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Thurs	No deals
Fri	No deals

View All Syndicate Announcements »

Verizon in focus as former AOL chief Armstrong confirms exit

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access